Companies and Researchers to Showcase Innovation in the Treatment of Seizures Family Education Day Registration on June 7th Has Reached Capacity
The Epilepsy Foundation announced today that the 4th Biennial Epilepsy Pipeline Conference 2014, an initiative of the Epilepsy Therapy Project, will feature a stellar line up of therapeutic and medical device developers, clinical investigators and industry leaders presenting the latest epilepsy therapies in development. The conference will highlight the most pressing issues faced by the epilepsy community today including the evaluation of medical marijuana; how to accelerate epilepsy research innovation to the next stage; and the urgent unmet need for new therapies for the millions of people with epilepsy who are not receiving adequate seizure control. This year’s conference will also feature the annual “Shark Tank ” competition where new ideas arising from researchers and entrepreneurs are invited to compete for funding that will advance their inventive product concepts with the promise of improving the lives of people with epilepsy. The Epilepsy Pipeline Conference will be held on June 5-7, 2014, at the Hyatt Regency San Francisco.
Companies and organizations selected by the Epilepsy Foundation’s prestigious Scientific and Business Advisory Boards to present their epilepsy products and programs in development include: Intellimedix, Asklepios BioPharmaceutical, AurimMed Pharma, BioCrea, EpaleX, Fluorinov Pharma, NeuroGate Therapeutics, NeuroGenomeX, INSYS Therapeutics, NeuroAdjuvants, University of South Florida, SciFluor Life Sciences, Sage Therapeutics, Cyberonics, Brain Sentinel, Epitel, Empatica, Smart Monitor, RTI International, Medtronic, NeuroSigma, UCLA, Visualase, Swedish Neuroscience Institute, Boston Children’s Hospital, Ultragenyx Pharmaceutical, Alexza Pharmaceuticals, Convergence Pharmaceuticals, GW Pharmaceuticals, Insero Health, Marinus Pharmaceuticals, SK Life Science, UCB and Vertex Pharmaceuticals.
Pharmaceutical, biotechnology and device industry executives, investors, clinical scientists, technology transfer executives and the epilepsy community are invited to hear directly from leaders in the field and register to attend the 2014 Epilepsy Pipeline Conference at: http://bit.ly/PipelineConference . All registrants are encouraged to take advantage of early bird registration rates through May 12, 2014.
“The Epilepsy Pipeline Conference is recognized as the scientific, industry and funding forum for those seeking support for new approaches that leverage both what we understand and are learning today about epilepsy and seizure conditions,” said Philip M. Gattone, President and CEO of the Epilepsy Foundation. “We are taking a hands-on role in advocating, funding and urging all industry partners and innovators to accelerate their products through development and ultimately to people living with seizures.”
